0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Hepagene Therapeutics Receives Fda Clearance For Hpg7233 Thr Beta Agonist Ind Application
News Feed
course image
  • 22 Sep 2023
  • Admin
  • News Article

Hepagene Therapeutics Receives FDA Clearance for HPG7233 THR Beta Agonist IND Application

Hepagene Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for HPG7233, a Thyroid Hormone Receptor beta (THR-β) agonist designed to address the pressing needs of patients suffering from non-alcoholic steatohepatitis (NASH) and dyslipidemia.

HPG7233 represents a remarkable advancement in therapeutic innovation. It stands out as a liver-targeted, highly selective small molecule thyroid hormone receptor beta (THR-β) agonist that targets serum and liver lipid metabolism with exceptional precision. 

Furthermore, HPG7233 has demonstrated excellent selectivity for target tissues, offering an added layer of safety and specificity. Toxicology studies have provided results, with no adverse findings related to THR-α subtypes or gastrointestinal tract issues, confirming its suitability for clinical development.

The preclinical studies have demonstrated its exceptional selectivity, potency, and its ability to greatly enrich the liver while maintaining an optimal liver/plasma exposure profile in both rodent and non-rodent animal models. Moreover, HPG7233 has consistently shown its ability to significantly reduce liver triglyceride levels, lower serum LDL-C (Low-Density Lipoprotein Cholesterol), and effectively reduce the NAS (NAFLD Activity Score) in NASH animal models.

Based on its preclinical profile, HPG7233 holds the promise of becoming the next generation THR-β agonist, offering new hope and potential for patients grappling with NASH and dyslipidemia.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form